Showing results (1471-1480 of 1,518) with videos related to

Sort By:
Pageof 152
Clinical Lung Cancer|May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and TechnologiesFred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancerP D Bonomi, D Gandara, F R Hirsch, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trialR A Soo, K Vervita, M Früh, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 3, 2019
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul M Putora, Markus Glatzer, José Belderbos, et al.
NPJ Precision Oncology|April 1, 2022
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapyTimothy Rajakumar, Rastislav Horos, Julia Jehn, et al.
Lancet (London, England)|June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trialLuis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Cancer Cell|February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeBarzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialS Peters, J-L Pujol, U Dafni, et al.
Pageof 152